Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma

BACKGROUND: Cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over lomustine in relapsed glioblastoma. One resistance mechanism for cediranib is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to det...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: Brown, Nicholas, McBain, Catherine, Nash, Stephen, Hopkins, Kirsten, Sanghera, Paul, Saran, Frank, Phillips, Mark, Dungey, Fiona, Clifton-Hadley, Laura, Wanek, Katharina, Krell, Daniel, Jeffries, Sarah, Khan, Iftekhar, Smith, Paul, Mulholland, Paul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4883746/
https://ncbi.nlm.nih.gov/pubmed/27232884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0156369
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia